NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has announced an equity award granted to a new employee as an inducement to join the company, effective June 24, 2026. The grant was approved by the company's independent directors under NeuroOne's 2021 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
The individual, who was not a previous employee or director, received an option to purchase 10,000 shares of common stock at an exercise price of $3.27 per share, equal to the closing price on the grant date. The option has a ten-year term and vests over four years, with 25% vesting on June 24, 2027, and the remainder vesting in equal quarterly installments thereafter, contingent on continued employment.
This disclosure is required because the award is not made under a stockholder-approved equity plan, as per Nasdaq rules. Such inducement grants are common for attracting key talent, particularly in the competitive medical technology sector.
NeuroOne focuses on improving surgical care for neurological disorders. Its product families include Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for the brain, and OneRF Trigeminal Nerve Ablation System. The company also has research and development programs in drug delivery, basivertebral nerve ablation, and spinal cord stimulation.
For more information about NeuroOne, visit nmtc1.com. Investor relations are handled by MZ North America at NMTC@mzgroup.us.
